News|Videos|November 13, 2023
Treatment Choices for Recurrent dMMR Endometrial Cancer
Author(s)Ritu Salani, MD, Bhavana Pothuri, MD
Exploring treatment options for patients with recurrent mismatch repair deficient endometrial cancer, including the choice between single-agent checkpoint inhibitors and chemo-immunotherapy combinations, with insights from GARNET and KEYNOTE-158 studies.
Advertisement
Episodes in this series
Advertisement
Related to this article
Dana Chase, MD, discusses why B7-H4 has emerged as a promising antibody-drug conjugate target in ovarian and endometrial cancer.
Advertisement
Advertisement
Trending on OncLive
1
Tam-Peli Reduces Risk of Death by 54% vs Topotecan in Relapsed SCLC
2
Ris-Rez Extends Median OS to 18.5 Months vs Topotecan in Relapsed SCLC
3
Iza-Bren Elicits 33% ORR, 6.9-Month PFS in Post-Osimertinib EGFR-Mutated NSCLC
4
Dr Liu on Building on the ADRIATIC Regimen in Limited-Stage Small Cell Lung Cancer
5